Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions-Reference-Cited by-同舟云学术

Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions

Published:2019-06-25 Issue:24 Volume:321 Page:2463
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Fu Wayne¹,Smith Cambray²,Turner Leigh³,Fojtik Joseph⁴,Pacyna Joel E.²,Master Zubin²

Affiliation:

1. Albany Medical College, Albany, New York

2. Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota

3. University of Minnesota Center for Bioethics, Minneapolis

4. Illinois Department of Financial and Professional Regulations, Chicago

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jama/article-pdf/321/24/2463/17671740/jama_fu_2019_ld_190020.pdf

Reference6 articles.

1. The US direct-to-consumer marketplace for autologous stem cell interventions.;Turner;Perspect Biol Med,2018

2. Selling stem cells in the USA: assessing the direct-to-consumer industry.;Turner;Cell Stem Cell,2016

3. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions.;Bauer;Stem Cells Transl Med,2018

4. American Board of Medical Specialties. ABMS Guide to Medical Specialties. https://www.abms.org/member-boards/specialty-subspecialty-certificates/. Published 2019. Accessed April 5, 2019.

5. Federation of State Medical Boards. Position statement on practice drift. https://www.fsmb.org/siteassets/advocacy/policies/position-statement-on-practice-drift.pdf. Published April 2016. Accessed March 23, 2019.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation;Cytotherapy;2024-02

2. Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies;Regenerative Medicine;2023-10

3. International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products;Cytotherapy;2023-09

4. Difficulties in ensuring review quality performed by committees under the Act on the Safety of Regenerative Medicine in Japan;Stem Cell Reports;2023-03

5. The two-bucket problem of unproven stem cell interventions;Regenerative Medicine;2023-01